Latest Articles

Publication Date
All News Scientific
Cancer Risk Profile of the Levonorgestrel-Releasing Intrauterine Device: A Narrative Review.

Background/Objectives: The levonorgestrel-releasing intrauterine device (LNG-IUD) is widely used as a long-acting reversible contraceptive and as a therapeutic option for heavy menstrual bleeding, endometriosis, adenomyosis, and endometrial hyperplasia. Although its …

Published: July 23, 2026, midnight
Read Full Article
breast cancer cancer risk endometrial cancer hormonal intrauterine system levonorgestrel-releasing intrauterine device ovarian cancer
Premenopausal and postmenopausal obesity and endometrial cancer risk: circulating biomarkers of inflammation, insulin resistance, and sex hormones as mediators - Escuela Andaluza de Salud Pública

Premenopausal and postmenopausal obesity and endometrial cancer risk: circulating biomarkers of inflammation, insulin resistance, and sex hormones as mediators Escuela Andaluza de Salud Pública

Published: July 22, 2026, 9:19 a.m.
Read Full Article
Merck's Keytruda Meets Primary Endpoint in Phase 3 Frontline Endometrial Cancer Trial - BioPharm International

Merck's Keytruda Meets Primary Endpoint in Phase 3 Frontline Endometrial Cancer Trial BioPharm International

Published: July 16, 2026, 9:06 p.m.
Read Full Article
Giuseppe Caruso: KEYTRUDA Improves Progression-Free Survival in Frontline dMMR Endometrial Cancer - Oncodaily

Giuseppe Caruso: KEYTRUDA Improves Progression-Free Survival in Frontline dMMR Endometrial Cancer Oncodaily

Published: July 16, 2026, 4:40 p.m.
Read Full Article
Pembrolizumab Monotherapy Improves PFS in Frontline dMMR Endometrial Cancer - CancerNetwork

Pembrolizumab Monotherapy Improves PFS in Frontline dMMR Endometrial Cancer CancerNetwork

Published: July 16, 2026, 3:40 p.m.
Read Full Article
Merck Says Blockbuster Keytruda Outperforms Chemotherapy in Advanced Endometrial Cancer - Sahm

Merck Says Blockbuster Keytruda Outperforms Chemotherapy in Advanced Endometrial Cancer Sahm

Published: July 16, 2026, 10:27 a.m.
Read Full Article
Onconic's Nesuparib Targets 26 Trillion Won Endometrial Cancer Market, Backed by SCI Paper - Seoul Economic Daily

Onconic's Nesuparib Targets 26 Trillion Won Endometrial Cancer Market, Backed by SCI Paper Seoul Economic Daily

Published: July 16, 2026, 5:33 a.m.
Read Full Article
Merck's (MRK) Keytruda Becomes First PD-1 Inhibitor To Beat Chemotherapy Alone In Endometrial Cancer Subtype - londoninsider.co.uk

Merck's (MRK) Keytruda Becomes First PD-1 Inhibitor To Beat Chemotherapy Alone In Endometrial Cancer Subtype londoninsider.co.uk

Published: July 15, 2026, 11:49 p.m.
Read Full Article
Merck touts Keytruda front-line win in endometrial cancer subtype, marking a PD-1 first - Fierce Pharma

Merck touts Keytruda front-line win in endometrial cancer subtype, marking a PD-1 first Fierce Pharma

Published: July 15, 2026, 7:33 p.m.
Read Full Article
Merck posts late-stage trial win for frontline Keytruda in endometrial cancer - MSN

Merck posts late-stage trial win for frontline Keytruda in endometrial cancer MSN

Published: July 15, 2026, 6:22 p.m.
Read Full Article
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!